SM is characterized by specific pathological mutations in exon 17 of the tyrosine kinase KIT (mainly KITD816V) and mutation-dependent histological and immunohistochemical findings, as described in the World Health Organization (WHO) criteria for diagnosis of SM [4]. This evidence concerns the gene KIT and systemic mastocytosis.